WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™
- None.
- None.
WuXiBodyTM has been widely adopted globally since its launch in 2018. It can effectively break through the CMC barriers for the development of many bispecific antibodies with high expression yield, high stability, good solubility, and easy purification to homogeneity. Additionally, it can shorten the process by 6-18 months and significantly reduce manufacturing costs compared to many other current bispecific platforms.
The WuXiBodyTM platform enables almost any mAb sequence pairs to be assembled into bispecific constructs that are expected to have low immunogenicity risk and a long in vivo half-life. It offers unique structural flexibility, which makes it convenient for building various formats with different combinations of valencies (1+1, 1+2, 2+2), and is also compatible with different Fc domains to meet the requirements of different target biologies.
Dr. Chris Chen, CEO of WuXi Biologics, commented, "We're proud that our WuXiBodyTM platform was granted the
As of December 31, 2023, there are 45 out-licensed WuXiBodyTM projects in various stages -- four of which are in Phase Ⅰ clinical development. Further demonstrating the value of WuXiBodyTM's state-of-the-art technology, investigational New Drug (IND) applications of two WuXiBodyTM projects are expected be approved in 2024.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
Contacts
Business
Info@wuxibiologics.com
Media
PR@wuxibiologics.com
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-granted-us-patent-for-proprietary-bispecific-antibody-technology-platform-wuxibody-302035834.html
SOURCE WuXi Biologics
FAQ
What is the name of the company mentioned in the press release?
What is the ticker symbol for WuXi Biologics?
What is the name of the proprietary engineering platform mentioned in the press release?
In which countries was the patent for WuXiBodyTM granted?
How many out-licensed WuXiBodyTM projects were there as of December 31, 2023?
How many WuXiBodyTM projects are in Phase Ⅰ clinical development?